Biomerica, Inc. (BMRA) EPS Estimated At $-0.05

March 15, 2018 - By Adrian Erickson

 Biomerica, Inc. (BMRA) EPS Estimated At $ 0.05
Investors sentiment increased to 0.25 in 2017 Q3. Its up 0.25, from 0 in 2017Q2. It improved, as 2 investors sold Biomerica, Inc. shares while 2 reduced holdings. 1 funds opened positions while 0 raised stakes. 66,682 shares or 11.38% less from 75,249 shares in 2017Q2 were reported.
Millennium Llc, New York-based fund reported 27,023 shares. Malaga Cove Limited Liability Corporation has invested 0.03% in Biomerica, Inc. (NASDAQ:BMRA). 10,077 were reported by Panagora Asset. North Star Management accumulated 0% or 250 shares. Wells Fargo & Mn holds 0% or 6,500 shares. Bancshares Of America Corp De reported 3,832 shares.

Since January 23, 2018, it had 4 insider buys, and 0 selling transactions for $65,333 activity. CANO FRANCIS bought $49,324 worth of Biomerica, Inc. (NASDAQ:BMRA) on Wednesday, January 24.

Analysts expect Biomerica, Inc. (NASDAQ:BMRA) to report $-0.05 EPS on April, 13.They anticipate $0.01 EPS change or 25.00 % from last quarter’s $-0.04 EPS. After having $-0.03 EPS previously, Biomerica, Inc.’s analysts see 66.67 % EPS growth. The stock decreased 4.40% or $0.19 during the last trading session, reaching $4.13. About 39,567 shares traded. Biomerica, Inc. (NASDAQ:BMRA) has risen 66.46% since March 15, 2017 and is uptrending. It has outperformed by 49.76% the S&P500.

Biomerica, Inc., together with its subsidiaries, develops, makes, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company has market cap of $35.28 million. The companyÂ’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It currently has negative earnings. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests.

More notable recent Biomerica, Inc. (NASDAQ:BMRA) news were published by: which released: “Form 8-K BIOMERICA INC For: Dec 01” on March 08, 2018, also with their article: “China Food and Drug Administration (CFDA) approves Biomerica colorectal …” published on January 10, 2018, published: “Biomerica Reports 1st Quarter Fiscal 2018 Financials” on October 17, 2017. More interesting news about Biomerica, Inc. (NASDAQ:BMRA) were released by: and their article: “Biomerica Extends Exclusive License Agreement with Celtis Pharm (Telcon …” published on November 07, 2017 as well as‘s news article titled: “Biomerica Inc.” with publication date: May 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.